Gilead Sciences, Inc. (NASDAQ: GILD) is considered one of the best slow growth stocks to invest in, with Mizuho increasing its price target to $140 on November 21 due to factors such as a longer exclusivity period for Biktarvy. The pre-exposure prophylaxis market for Yeztugo was also noted to have potential reaching $15-20 billion.

However, Gilead Sciences, Inc. (NASDAQ: GILD) faced challenges as its cancer medication Trodelvy failed to meet its primary objective in a Phase 3 trial for HR+/HER2-negative metastatic breast cancer, compared against chemotherapy. The ASCENT-07 trial did not achieve its main goal of progression-free survival.

Gilead Sciences Inc. (NASDAQ: GILD) is a biopharmaceutical company that develops and commercializes medicines in areas of unmet medical need globally. Despite its potential as an investment, some believe that certain AI stocks offer greater upside potential and less downside risk.

For more information on potential investments, check out Insider Monkey for reports on the best short-term AI stock, 10 Best Magic Formula Stocks for 2025, and 10 Best Retirement Stocks to Buy According to Hedge Funds. Disclosure: None.

Read more at Yahoo Finance: Mizuho Lifts Target Amid Stronger Biktarvy Timeline